TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03434041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
Study: NCT02541071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02780804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02506335

Intervention type: DRUG
Group type: OTHER
Intervention: Cholate testing
Description: The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
Study: NCT04091503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Modified Temozolomide
Description: Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Modified Temozolomide
Description: Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Modified Temozolomide
Description: Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated
Study: NCT03079219

Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Aprepitant
Description: Day 1: 125mg QD, Day 2 to Day3: 80mg QD

Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Ondansetron
Description: Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose

Intervention type: DRUG
Group type: OTHER
Intervention: Standard: Dexamethasone
Description: Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
Study: NCT00421135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-201
Description: ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
Study: NCT01785576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based CBT Intervention
Description: Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
Study: NCT03123328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radical-7 Pulse CO-Oximeter and sensor
Description: Noninvasive device that measures hemoglobin.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Substance misuse screening
Description: Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Substance misuse screening
Description: Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
Study: NCT03506750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Substance misuse screening
Description: Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)

Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D
Description: Health related Quality of life
Study: NCT03506750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVC
Description: Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D
Description: Health related Quality of life

Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D
Description: Health related Quality of life
Study: NCT02221011

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulsivity screening
Description: Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
Study: NCT03506750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and aqueous humor at the time of IVC
Description: Initial blood and aqueous humor will be harvested at the time of IVC.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulsivity screening
Description: Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test

Intervention type: DIAGNOSTIC_TEST
Intervention: Impulsivity screening
Description: Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive screening
Description: Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive screening
Description: Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
Study: NCT03506750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive screening
Description: Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional tests
Description: Timed up and go (TUG), Single leg balancing test (SLB)
Study: NCT03506750

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Collect blood, aqueous humor, and initial vitreous at the time of surgery.
Description: Blood, aqueous humor, and vitreous will be collected at the time of surgery.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional tests
Description: Timed up and go (TUG), Single leg balancing test (SLB)
Study: NCT02221011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases.
Study: NCT02458274

Intervention type: OTHER
Intervention: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)

Intervention type: OTHER
Intervention: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)
Study: NCT04222088

Intervention type: DRUG
Intervention: Arthemeter-lumefantrine
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)

Intervention type: DRUG
Intervention: Chloroquine
Description: Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)

Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.

Intervention type: DRUG
Intervention: Primaquine
Description: For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
Study: NCT03311997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical reattachment of hamstring tendons
Description: operatively reattachment of the tendons using suture anchor
Study: NCT01071317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500mg PO bid prn headache
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional tests
Description: Timed up and go (TUG), Single leg balancing test (SLB)

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognistat
Description: Assessment of cognitive domains

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognistat
Description: Assessment of cognitive domains
Study: NCT03506750

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IVC-sham
Description: Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
Study: NCT03162081

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological profiling
Description: Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological profiling
Description: Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test

Intervention type: OTHER
Intervention: Clinical interview
Description: Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale

Intervention type: OTHER
Intervention: Clinical interview
Description: Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale

Intervention type: OTHER
Intervention: Clinical interview
Description: Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale

Intervention type: OTHER
Intervention: Medication use
Description: Detailed screen of used medications, interactions, side effects in electronic patient registry

Intervention type: OTHER
Intervention: Medication use
Description: Detailed screen of used medications, interactions, side effects in electronic patient registry

Intervention type: OTHER
Intervention: Medication use
Description: Detailed screen of used medications, interactions, side effects in electronic patient registry

Intervention type: OTHER
Intervention: Comorbidity
Description: Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
Study: NCT02801942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node fine needle aspirate biopsy
Description: Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
Study: NCT03162081

Intervention type: OTHER
Intervention: Comorbidity
Description: Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
Study: NCT02801942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node fine needle aspirate biopsy
Description: Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node core biopsy
Description: Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal lymph node core biopsy
Description: Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.